FCA
UBX

FinTrust Capital Advisors’s Unity Biotechnology UBX Stock Holding History

FinTrust Capital Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-65
Closed -$1K – 1310
2022
Q1 		$1K Hold
65
– – ﹤0.01% 1190
2021
Q4 		$1K Buy
+65
New +$1.42K ﹤0.01% 1158

Other funds holding UBX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's UBX Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Unity Biotechnology (UBX) in Q2 2022, closing a stake of 65 shares — an estimated $1K sold.

FinTrust Capital Advisors first reported a position in UBX in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 65 funds tracked by Wall St. Rank hold UBX as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Unity Biotechnology position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 65 Unity Biotechnology shares in Q2 2022, an estimated $1K.
  • FinTrust Capital Advisors first reported a position in Unity Biotechnology in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Unity Biotechnology position peaked at $1K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.